Skip to main content

Table 3 Published phase 1/2 studies of olaratumab

From: PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy

Author Phase N Diagnosis ORR CBR PFS OS
Chiorean [69] 1 19 Solid tumors 0 NA NA NA
Doi [68] 1 16 Solid tumors 0 NA NA NA
Tap [70] 1b 15 Soft tissue sarcoma NA NA NA NA
Tap [70] 2 129 Soft tissue sarcoma Olaratumab+ ADM 18.2%
ADM alone 11.9%
NA 6.6 months
4.1 months
26.5
14.7
Wagner [25] 2 21 GIST PDGFR-a mutation(+)
PDGFR-a mutation(−)
50.0
14.3
32.1 weeks
6.1 weeks
NR
24.9 weeks
Gerber [23] 2 131 NSCLC olaratumab+ P/C
P/C
NA 4.4 months
4.4 months
11.8 months
11.5 months
  1. N number; ORR objective response rate, =CR+PR; CBR clinical benefit rate, =CR+PR+SD at 12 weeks; PFS progression free survival; OS overall survival; NA not available; ADM adriamycin; NR not reached; P/C paclitaxel/carboplatin